Acute voluntary intoxication with selective serotonin reuptake inhibitors during the third trimester of pregnancy: therapeutic management of mother and fetus

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 5, 2008, Pages e9-

  Tixier, Hervé ^a   Feyeux, Cecile ^a   Girod, Sophie ^a   Thouvenot, Ségoléne ^a   Morisse, Mathieu ^a   Douvier, Serge ^a   Sagot, Paul ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

pregnancy; selective serotonin reuptake inhibitor; voluntary intoxication

Indexed keywords

ACTIVATED CARBON; ALPRAZOLAM; BETAMETHASONE; ESCITALOPRAM; NICARDIPINE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG DETOXIFICATION; DRUG MECHANISM; DRUG OVERDOSE; FEMALE; HUMAN; PRIORITY JOURNAL; STOMACH LAVAGE; THIRD TRIMESTER PREGNANCY;

EID: 54849404928     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.07.024     Document Type: Article

References (14)

1. Boyer E.W., and Shannon M. The serotonin syndrome. N Engl J Med 352 (2005) 1112-1120
2. Minosyan T.Y., Lu R., Eghbali M., Toro L., and Stefani E. Increased 5-HT contractile response in late pregnant rat myometrium is associated with a higher density of 5-HT2A receptors. J Physiol 581 (2007) 91-97
3. Heikkine T., Ekblad U., and Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG 109 (2002) 1003-1008
4. Hendrick V., Smith L.M., Suri R., Hwang S., Haynes D., and Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188 (2003) 812-815
5. Nordeng H., and Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf 28 (2005) 565-581
6. Oberlander T.F., Warburton W., Misri S., Aghajanian J., and Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63 (2006) 898-906
7. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354 (2006) 579-587
8. Malm H., Klaukka T., and Neuvonen P.J. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 106 (2005) 1289-1296
9. Way C.M. Safety of newer antidepressants in pregnancy. Pharmacotherapy 27 (2007) 546-552
10. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., and Friedman J.M. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356 (2007) 2684-2692
11. Laine K., Heikkinen T., Ekblad U., and Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 60 (2003) 720-726
12. Moses-Kolko E.L., Bogen D., Perel J., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293 (2005) 2372-2383
13. Sivojelezova A., Shuhaiber S., Sarkissian L., Einarson A., and Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 193 (2005) 2004-2009
14. Paruchuri P., Godkar D., Anandacoomarswamy D., Sheth K., and Niranjan S. Rare case of serotonin syndrome with therapeutic doses of paroxetine. Am J Ther 13 (2006) 550-552